RPCEC00000115已完成3 期
se of alpha interferon in the treatment of the maintenance phase of multiple myeloma.
Center for Genetic Engineering and Biotechnology (CIGB), in Havana.0 个研究点目标入组 65 人开始时间: 2011年5月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 /A (No limit)（—）
- 性别
- All
入选标准
- •1) Patients over 18 years. 2) Willingness of the individual by signing written consent. 3) Patients with multiple myeloma stage II / III according to Salmon and Durie classification. 4) Patients who have received favorable response to chemotherapy with a minimum of 6 months of treatment.
排除标准
- •1) Pregnancy or lactation. 2) Women of childbearing age who are hormonal contraceptive therapy or have no control over fertility. 3) Hypersensitivity to interferon or other preparations used in the study. 4) Acute or chronic liver (twice the normal value of TGP and TGO and / or total bilirubin > 1.5). 5) Decompensated heart failure. 6) Organic brain disease with symptoms that interfere with patient assessment so as to consent (eg Parkinson disease). 7) Major psychiatric disorder or other constraints that prevent the patient's consent. 8) Autoimmune diseases not related to multiple myeloma.
研究者
相似试验
已完成
4 期
InCroMiel IChronic Myeloid Leukemia.Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, MyeloidMyeloproliferative DisordersBone Marrow DiseasesHemic DiseasesLeukemiaRPCEC00000050Center for Genetic Engineering and Biothecnology (CIGB), in Havana.60
进行中（未招募）
不适用
Treatment with leucocytic interferon-alpha more ribavirine towards peg-interferon to reduced doses more ribavirine in patients affections from positive chronic hepatitis HCV that in course of arranged therapy demand the reduction of the peghilato dosage of interferon. - NDEUCTR2005-005161-11-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI200
招募中
不适用
Combination therapy of interferon-alpha and interleukin-2 for patients with metastatic renal cell carcinoma after failure of targeted therapy because of adverse eventsJPRN-UMIN000017717Department of Urology, The University of Tokyo Hospital30
已完成
2 期
REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis PatientsMultiple SclerosisNCT01171209Melinda Magyari10
已完成
3 期
Effect of administration of interferon alfa 2-b in treatment of pterygiumpterygium of eye.Pterygium of eyeH11.0IRCT20120817010617N5Zahedan University of Medical Sciences60